Bortezomib vs TQB3602

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: Proteasome · full Multiple Myeloma pipeline

Bortezomib

Marketed by Takeda Pharmaceutical Company and partners

Approved in Multiple Myelomasmall molecule (proteasome inhibitor)
Partial signal

NCT00048230 · Phase 3 · completed

APEX randomized 620 patients with relapsed multiple myeloma to bortezomib or high-dose dexamethasone in an open-label design. Its primary endpoint, time to progression, is a clinical outcome and was met. An open-label trial is never graded strong under the rubric, so the grade is moderate.

Next expected readout: November 2026 · NCT06505369 (registry estimate)

Reported efficacy

Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73 (met)

Result source: NCT00722566

TQB3602

Developed by Sino Biopharmaceutical

Phase 1 in Multiple Myelomasmall molecule
Weak signal

NCT04275583 · Phase 1 · status unknown

This is a small, open-label, single-arm, non-randomized dose-finding study designed to establish tolerability rather than to test clinical benefit, with no comparator arm and no blinding. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

These results cover the 25-patient dose-escalation phase; the study's dose-expansion phase is not included.

Reported efficacy

Dose-limiting toxicity (DLT) (Baseline up to 28 days): Twenty-five patients with relapsed/refractory multiple myeloma who had relapsed or failed at least 2 lines of therapy were enrolled in the dose-escalation phase. Two patients in the 7.0 mg dose group developed dose-limiting toxicities, giving a maximum tolerated dose of 6.0 mg. Any-grade adverse events occurred in 24 (96.0%) patients and grade >=3 adverse events in 13 (52.0%). Among 22 response-evaluable patients, 63.7% achieved stable disease or better.

Result source: NCT04275583

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBortezomibTQB3602
PFS, median11.2 vs 7.1vs BTZ+LD-DEXn 281NCT01734928
14 other results
—Not reported
OS, median83.0 vs 53.6vs Velcade, Melphalan and Prednisonen 350NCT02195479
10 other results
—Not reported
ORR90.9% vs 73.9%vs Velcade, Melphalan and Prednisonen 350NCT02195479
12 other results
—Not reported
VGPR or better71.1% vs 49.7%vs Velcade, Melphalan and Prednisonen 350NCT02195479
8 other results
—Not reported
MRD negativity53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)n 197NCT03652064
5 other results
—Not reported

PFS, median

Bortezomib
11.2 vs 7.1vs BTZ+LD-DEXn 281NCT01734928
14 other results
TQB3602
—Not reported

OS, median

Bortezomib
83.0 vs 53.6vs Velcade, Melphalan and Prednisonen 350NCT02195479
10 other results
TQB3602
—Not reported

ORR

Bortezomib
90.9% vs 73.9%vs Velcade, Melphalan and Prednisonen 350NCT02195479
12 other results
TQB3602
—Not reported

VGPR or better

Bortezomib
71.1% vs 49.7%vs Velcade, Melphalan and Prednisonen 350NCT02195479
8 other results
TQB3602
—Not reported

MRD negativity

Bortezomib
53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)n 197NCT03652064
5 other results
TQB3602
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

TQB3602
Twenty-five patients with relapsed/refractory multiple myeloma who had relapsed or failed at least 2 lines of therapy were enrolled in the dose-escalation phase. Two patients in the 7.0 mg dose group developed dose-limiting toxicities, giving a maximum tolerated dose of 6.0 mg. Any-grade adverse events occurred in 24 (96.0%) patients and grade >=3 adverse events in 13 (52.0%). Among 22 response-evaluable patients, 63.7% achieved stable disease or better. NCT04275583 · Phase 1 · design grade: weak · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Bortezomib: 4 of 4 rows · TQB3602: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBortezomib
Dropout rate
47.3%VELCADE Intravenousa
NCT00722566 · Phase 3
show 32 more results
45.3%VELCADE Subcutaneous
NCT00722566 · Phase 3
n/a: no completion milestone
NCT03652064 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—DVTd - Part 1
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
—DVTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—VTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—Treatment 1: POM + BTZ + LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
1.1%Treatment 1: POM+BTZ+LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneSVd Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—SVdX Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
15%Arm A: VELCADE, CYCLOPHOSPHAMIDE,
NCT01146834 · Phase 3 · registry result, not featured evidence
0%Arm B: VELCADE & G-CSF
NCT01146834 · Phase 3 · registry result, not featured evidence
—Arm E: PLERIXAFOR, VELCADE, & G-CS
NCT01146834 · Phase 3 · registry result, not featured evidence · combination
0%
NCT01109004 · Phase 3 · registry result, not featured evidence
20.7%Bortezomib + Cyclophosphamide + De
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
—Bortezomib + Thalidomide + Prednis
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneDoxil/Caelyx Plus Velcade (Bortezo
NCT00103506 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneVelcade (Bortezomib) Monotherapy
NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy
70.2%Bortezomib and Dexamethasone
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
68.3%Bortezomib, Melphalan and Predniso
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
74.9%Bortezomib, Thalidomide, and Dexam
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
68.1%
NCT00813150 · Phase 3 · registry result, not featured evidence · combination
64.3%
NCT01801436 · Phase 3 · registry result, not featured evidence
71.6%D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
1.5%Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
78.5%Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
15.4%
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02703779 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePart 1 - Bortezomib + Siltuximab
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 2 - Bortezomib + Siltuximab
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
87.1%
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—VELCADE Intravenousa
NCT00722566 · Phase 3
show 32 more results
—VELCADE Subcutaneous
NCT00722566 · Phase 3
—
NCT03652064 · Phase 3 · registry result, not featured evidence
—
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
—
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—DVTd - Part 1
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
—DVTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—VTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—Treatment 1: POM + BTZ + LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
—Treatment 1: POM+BTZ+LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
0.5%SVd Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—SVdX Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—Arm A: VELCADE, CYCLOPHOSPHAMIDE,
NCT01146834 · Phase 3 · registry result, not featured evidence
—Arm B: VELCADE & G-CSF
NCT01146834 · Phase 3 · registry result, not featured evidence
—Arm E: PLERIXAFOR, VELCADE, & G-CS
NCT01146834 · Phase 3 · registry result, not featured evidence · combination
—
NCT01109004 · Phase 3 · registry result, not featured evidence
5.5%Bortezomib + Cyclophosphamide + De
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
—Bortezomib + Thalidomide + Prednis
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
—Doxil/Caelyx Plus Velcade (Bortezo
NCT00103506 · Phase 3 · registry result, not featured evidence · combination
—Velcade (Bortezomib) Monotherapy
NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy
34.5%Bortezomib and Dexamethasone
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
38.9%Bortezomib, Melphalan and Predniso
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
40.1%Bortezomib, Thalidomide, and Dexam
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
31.9%
NCT00813150 · Phase 3 · registry result, not featured evidence · combination
14.3%
NCT01801436 · Phase 3 · registry result, not featured evidence
—D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
—Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
—Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
—
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
—
NCT02703779 · Phase 2 · registry result, not featured evidence
33.3%Part 1 - Bortezomib + Siltuximab
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
19%Part 2 - Bortezomib + Siltuximab
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
64.5%
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
35.1%VELCADE Intravenousa
NCT00722566 · Phase 3
show 32 more results
36.1%VELCADE Subcutaneous
NCT00722566 · Phase 3
72.1%
NCT03652064 · Phase 3 · registry result, not featured evidence
53.8%
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
55.1%
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
49.3%DVTd - Part 1
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
18.8%DVTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
27.5%VTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
63.7%Treatment 1: POM + BTZ + LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
—Treatment 1: POM+BTZ+LD-DEX
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
55.9%SVd Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
42.4%SVdX Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
0%Arm A: VELCADE, CYCLOPHOSPHAMIDE,
NCT01146834 · Phase 3 · registry result, not featured evidence
0%Arm B: VELCADE & G-CSF
NCT01146834 · Phase 3 · registry result, not featured evidence
—Arm E: PLERIXAFOR, VELCADE, & G-CS
NCT01146834 · Phase 3 · registry result, not featured evidence · combination
20.6%
NCT01109004 · Phase 3 · registry result, not featured evidence
34.6%Bortezomib + Cyclophosphamide + De
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
27.2%Bortezomib + Thalidomide + Prednis
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
37.7%Doxil/Caelyx Plus Velcade (Bortezo
NCT00103506 · Phase 3 · registry result, not featured evidence · combination
33%Velcade (Bortezomib) Monotherapy
NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy
53.3%Bortezomib and Dexamethasone
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
50.9%Bortezomib, Melphalan and Predniso
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
58.2%Bortezomib, Thalidomide, and Dexam
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
29.8%
NCT00813150 · Phase 3 · registry result, not featured evidence · combination
100%
NCT01801436 · Phase 3 · registry result, not featured evidence
44.8%D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
28.4%Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
56.9%Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
46.5%
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
48%
NCT02703779 · Phase 2 · registry result, not featured evidence
47.6%Part 1 - Bortezomib + Siltuximab
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
33.1%Part 2 - Bortezomib + Siltuximab
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
45.2%
NCT02290431 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
leukopenia 21.6%
fatigue 20.3%
constipation 14.9%
NCT00722566 · Phase 3
show 29 more results
leukopenia 19.7%
weight decreased 15%
constipation 14.3%
NCT00722566 · Phase 3
diarrhoea 56.3%
peripheral sensory neuropathy 55.8%
neutropenia 54.8%
NCT03652064 · Phase 3 · registry result, not featured evidence
neutropenia 50.3%
thrombocytopenia 49.7%
anaemia 31.8%
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
thrombocytopenia 59.7%
peripheral sensory neuropathy 50.2%
diarrhoea 36.2%
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
peripheral sensory neuropathy 60.6%
constipation 50.6%
asthenia 32.8%
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
bronchitis 40.6%
cough 17%
nasopharyngitis 17%
NCT02541383 · Phase 3 · registry result, not featured evidence
bronchitis 36.5%
cough 19.4%
nasopharyngitis 17.5%
NCT02541383 · Phase 3 · registry result, not featured evidence
neutropenia 54%
peripheral sensory neuropathy 48.2%
thrombocytopenia 39.6%
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
thrombocytopenia 61.5%
nausea 50.3%
fatigue 42.1%
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
thrombocytopenia 50%
anaemia 45.5%
nausea 39.4%
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
anemia 40%
nausea 35%
platelet count decreased 35%
NCT01146834 · Phase 3 · registry result, not featured evidence
platelet count decreased 100%
anemia 50%
generalized muscle weakness 50%
NCT01146834 · Phase 3 · registry result, not featured evidence
constipation 35.8%
nausea 32.3%
peripheral sensory neuropathy 24.4%
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 37.9%
peripheral sensory neuropathy 36.9%
neuropathy peripheral 29.1%
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
nausea 47.8%
diarrhoea 44.7%
fatigue 36.2%
NCT00103506 · Phase 3 · registry result, not featured evidence · combination
nausea 39.3%
diarrhoea 38.4%
constipation 30.8%
NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy
insomnia 5.5%
weight decreased 2.4%
blood sodium decreased 1.8%
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
leukopenia 7.4%
platelet count decreased 4.3%
insomnia 3.7%
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
hyperuricaemia 5.1%
insomnia 3.8%
cough 3.2%
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
fatigue 38.3%
thrombocytopenia 38.3%
diarrhoea 36.2%
NCT00813150 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 78.6%
white blood cell count decreased 78.6%
platelet count decreased 71.4%
NCT01801436 · Phase 3 · registry result, not featured evidence
thrombocytopenia 56.7%
anaemia 44.8%
constipation 44.8%
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
peripheral sensory neuropathy 41.8%
constipation 38.8%
neutropenia 37.3%
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
neutropenia 67.7%
diarrhoea 49.2%
anaemia 40%
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
fatigue 71.7%
upper respiratory tract infection 67.7%
diarrhoea 65.7%
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
diarrhea 58% (placebo 56.9%)
nausea 58% (placebo 64.7%)
anorexia 54% (placebo 51%)
NCT02703779 · Phase 2 · registry result, not featured evidence
neutropenia 81% (placebo 38.1%)
diarrhoea 61.9% (placebo 36%)
thrombocytopenia 61.9% (placebo 46.8%)
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
neutropenia 60.6% (placebo 38.1%)
thrombocytopenia 58.5% (placebo 46.8%)
peripheral sensory neuropathy 51.4% (placebo 52.5%)
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 80.6%
decreased appetite 58.1%
thrombocytopenia 54.8%
NCT02290431 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 30 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Bortezomib

ORR 42.1% (n=145)
event count · % of participants
No placebo or comparator arm
NCT00722566 · Phase 3 · converted to % from 61 Participants as posted
show 1 more result
42.5% (n=73)*
NCT00722566 · Phase 3 · converted to % from 31 Participants as posted
Complete 6.2% (n=145)
responder rate · % of participants
No placebo or comparator arm
NCT00722566 · Phase 3 · converted to % from 9 Participants as posted
show 4 more results
8.2% (n=73)*
NCT00722566 · Phase 3 · converted to % from 6 Participants as posted
3% (n=147)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
4% (n=133)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
4% (n=145)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
MRD Negative 53.3% (n=197) vs 35.4% (n=198) Bortezomib-lenalidomide-dexamethasone (VRd)
responder rate · % of participants
NCT03652064 · Phase 3 · registry result, not featured evidence
show 3 more results
60.9% (n=197) vs 39.4% (n=198) Bortezomib-lenalidomide-dexamethasone (VRd)
NCT03652064 · Phase 3 · registry result, not featured evidence
28.3% (n=350) vs 7% (n=356) Velcade, Melphalan and Prednisone
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
13.5% (n=251) vs 2.8% (n=247) Bortezomib + Dexamethasone
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
PFS NA vs 18.14 Velcade, Melphalan and Prednisone months
time to event · months
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
show 10 more results
36.4 vs 19.29 Velcade, Melphalan and Prednisone months
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
NA vs 7.16 Bortezomib + Dexamethasone months
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
11.2 vs 7.1 BTZ+LD-DEX months
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
13.93 vs 9.46 Bortezomib + Dexamethasone months
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
6.6 vs 8.84 Bortezomib + Dexamethasone months
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
3.88 vs 8.84 Bortezomib + Dexamethasone months
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
22.51 vs 22.05 Thalidomide + Prednisolone months
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
9.9 vs 12.6 Bortezomib + Dexamethasone months
NCT00813150 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Lenalidomide+Bortezomib+Dexamethasone months
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
8.05 vs 7.62 placebo months*
NCT00401843 · Phase 2 · registry result, not featured evidence · combination · converted to months from 245 days as posted
ORR 90.9% (n=350) vs 73.9% (n=356) Velcade, Melphalan and Prednisone
responder rate · % of participants
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
show 4 more results
82.9% (n=240) vs 63.2% (n=234) Bortezomib + Dexamethasone
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
76.4% (n=195) vs 62.3% (n=207) Bortezomib + Dexamethasone
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
70.2% (n=47) vs 74.4% (n=43) Bortezomib + Dexamethasone
NCT00813150 · Phase 3 · registry result, not featured evidence · combination
55% (n=131) vs 46.7% (n=137) placebo
NCT00401843 · Phase 2 · registry result, not featured evidence · combination
VGPR or Better 71.1% (n=350) vs 49.7% (n=356) Velcade, Melphalan and Prednisone
responder rate · % of participants
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
59.2% (n=240) vs 29.1% (n=234) Bortezomib + Dexamethasone
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
44.6% (n=195) vs 32.4% (n=207) Bortezomib + Dexamethasone
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
CR/sCR 42.6% (n=350) vs 24.4% (n=356) Velcade, Melphalan and Prednisone
responder rate · % of participants
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
Stringent Complete 18% (n=350) vs 7% (n=356) Velcade, Melphalan and Prednisone
responder rate · % of participants
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
show 5 more results
23.5% (n=98) vs 20.8% (n=96) Thalidomide + Prednisolone @ 13wk
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
28.6% (n=98) vs 27.1% (n=96) Thalidomide + Prednisolone @ 26wk
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
30.6% (n=98) vs 26% (n=96) Thalidomide + Prednisolone @ 39wk
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
28.6% (n=98) vs 26% (n=96) Thalidomide + Prednisolone @ 52wk
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
42.4% (n=99) vs 32% (n=97) Lenalidomide+Bortezomib+Dexamethasone
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
Overall Survival 82.96 vs 53.59 Velcade, Melphalan and Prednisone months
time to event · months
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
show 7 more results
49.58 vs 38.51 Bortezomib + Dexamethasone months
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
35.58 vs 31.61 BTZ+LD-DEX months
NCT01734928 · Phase 3 · registry result, not featured evidence · combination
36.67 vs 32.76 Bortezomib + Dexamethasone months
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
NA vs NA Thalidomide + Prednisolone months
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
41.5 vs NA Bortezomib + Dexamethasone months
NCT00813150 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Lenalidomide+Bortezomib+Dexamethasone months
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
30.78 vs 36.83 placebo months*
NCT00401843 · Phase 2 · registry result, not featured evidence · combination · converted to months from 937 days as posted
PFS2 66.73 vs 42.41 Velcade, Melphalan and Prednisone months
time to event · months
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
Time to Progression NA vs 19.35 Velcade, Melphalan and Prednisone months
time to event · months
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
NA vs 7.29 Bortezomib + Dexamethasone months
NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
9.9 vs 12.6 Bortezomib + Dexamethasone months
NCT00813150 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Lenalidomide+Bortezomib+Dexamethasone months
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
Time to Response 0.79 vs 0.82 Velcade, Melphalan and Prednisone months
time to event · months
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
1.41 vs 1.61 Bortezomib + Dexamethasone months
NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
0.8 vs 0.8 Lenalidomide+Bortezomib+Dexamethasone months
NCT02874742 · Phase 2 · registry result, not featured evidence · combination

+ 54 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bortezomib's landscape · TQB3602's landscape